{
    "nctId": "NCT03933319",
    "briefTitle": "Phase \u2161 Study of Pegylated Liposomal Doxorubicin\uff08PLD\uff09Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer",
    "officialTitle": "Phase \u2161 Study of Pegylated Liposomal Doxorubicin\uff08PLD\uff09Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Objective response rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to understand and voluntarily receive the research procedures according to protocol,willingness to sign the written informed consent document;\n* Female patients aged from 18 to 70 years old\uff1b\n* Histologically confirmed as invasive breast cancer\uff1b\n* HER-2 Positive\uff08defined by: IHC 3+ or ISH positive\uff09, regardless of HR status;\n* Recurrence after adjuvant therapy or metastatic breast cancer\uff0cand chemotherapy na\u00efve in the metastatic setting or had one prior regimen for metastatic breast cancer\uff1b\n* Patients must have measurable disease according to RECIST criteria Version 1.1\uff08Brain metastases lesions and bone metastases lesions were excluded\uff09;\n* The adverse event caused by prior therapy has recovered, or stabilized, or does not affect the study administration according to the investigator's judgment\uff1b\n* Performance status 0-1\uff1b\n* Life expectancy of at least 3 months\uff1b\n* Left ventricular ejection fraction (LVEF)\u226555%\uff1b\n* Brain natriuretic peptide (BNP) and cardiac troponin T (cTnT) were in the normal range\uff1b\n* Patients must have normal ECG\uff1b\n* Bone marrow function: absolute neutrophil count (ANC)\u22651.5\u00d7109/L\uff0cplatelets\u2265100\u00d7109/L\uff0chemoglobin \u226590g/L\uff1b\n* Hepatic function\uff1aalanine aminotransferase(ALT) and aspartate aminotransferase(AST) \u22642.5\u00d7ULN\uff0cserum total bilirubin\u2264 1.5\u00d7ULN\uff0cor \u22642.5\u00d7ULN who has Gilbert's syndrome;\n* Renal function\uff1aserum creatinine\u22641.5\u00d7ULN\uff1b\n* Coagulation function\uff1athe international standardized ratio (INR) \u22641.5\u00d7ULN, prothrombin time (PT) or the activated partial thrombin time (APTT) \u22641.5\u00d7ULN.\n\nExclusion Criteria:\n\n* Patients with symptomatic brain metastases.\n* Patients who are known or suspected to be allergic to the active ingredient or excipients of the investigational drug.\n* Prior cumulative dose of 240 mg/m2 for doxorubicin and 400 mg/m2 for epirubicin.\n* Prior treatment with anthracyclines has caused cardiotoxicity, or failed (disease progression during therapy or recurrence and metastasis within 12 months after adjuvant therapy).\n* Prior mediastinal radiotherapy.\n* Participation in other clinical trials within 4 weeks before enrollment.\n* Severe cardiovascular disease, including history of congestive heart failure, acute myocardial infarction within 6 months before enrollment, transmural myocardial infarction measured by ECG, uncontrolled arrhythmia, angina requiring therapy, clinically significant valvular heart disease, uncontrolled hypertension.\n* Severe or uncontrolled infection.\n* Positivity for HIV, Hepatitis B or C.\n* Active malignancy in the past 5 years (other than carcinoma in situ of the cervix or basal cell carcinoma of the skin).\n* Patients who are pregnant , breastfeeding ,or refuse to use adequate contraception during the course of participation.\n* Need to concurrent other cancer therapy(other than palliative care for non-target lesions).\n* Other ineligible conditions according to the researcher's judgment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}